Chroma Medicine Inc. closed a $135 million series B round as momentum builds at one of the early movers in the emerging field of epigenetic editing. It’s little more a year since Cambridge, Mass.-based Chroma emerged from stealth by disclosing a $125 million series A round and a stellar line-up of company founders. “It’s not all that long ago, but we have made a huge amount of progress,” CEO Catherine Stehman-Breen told BioWorld.
Current Surgical Inc. secured $3.2 million in a seed funding round to support development of its surgical needle platform to precisely destroy unresectable tumors. True Ventures led the round with participation from 1517 Fund and Scifounders.
Visionhealth GmbH will use the €3 million (US$3.2 million) it recently raised in a pre-series A financing to conduct a clinical trial on its digital health app designed to provide more accurate dosing of treatments for chronic obstructive pulmonary disease (COPD) and asthma.
Radiopharmaceutical company Fusion Pharmaceuticals Inc. is acquiring a phase II actinium-based alpha-emitter radiopharma program for prostate cancer from Radiomedix Inc.
Ophthalmic startup Eluminex Biosciences Ltd. closed a $40 million series B round to progress its pipeline of ophthalmic assets and recombinant human collagen technology. Eluminex’s pipeline includes multi-targeted antibody molecules for vision-threatening retinal diseases and an oral small molecule for rare inherited pediatric retinal dystrophies, but its lead asset, EB-301, is a biosynthetic cornea derived from recombinant human type III collagen.
Transthera Sciences Inc., a Nanjing, China-based company developing small-molecule therapies in cancer, inflammation and cardiovascular disease, raised ¥260 million (US$38 million) in a series D+ funding round to advance its first drug product.
Affluent Medical SA reported the imminent raising of nearly $14 million to fund development throughout 2023 of its implantable medical devices for treating urinary incontinence and heart valve pathology. Affluent, quoted on the Paris Euronext stock exchange since 2021, issued new shares accompanied by redeemable share warrants with shareholder preferential subscription rights being preserved.
RSS
